Preview

Rational Pharmacotherapy in Cardiology

Advanced search

COMPARATIVE EFFICACY OF THE STATINS IN PREVENTING AND TREATING OF THE CORONARY HEART DISEASE

https://doi.org/10.20996/1819-6446-2010-6-6-865-869

Full Text:

Abstract

The possibility to stabilize and reverse the atherosclerotic plaques in coronary arteries due to therapy with atorvastatin and rosuvastatin was demonstrated in recent studies. The advantage of aggressive lipid-lowering therapy compared with standard therapy is proven in patients with both stable and acute forms of ischemic heart disease (IHD). Pleiotropic effects, in particular, effect on endothelial function, ability to reduce the blood level of C-reactive protein are important in the statins mode of action. Risk reduction of cardiovascular complications and slow down of atherosclerosis progression in patients with IHD was significantly associated with decrease in levels of both atherogenic lipids and C-reactive protein.

About the Authors

S. V. Shalaev
Tyumen Medical Academy
Russian Federation
ul. Odesskaya 54, Tyumen, 625023


Z. M. Safiullina
Tyumen Medical Academy
Russian Federation
ul. Odesskaya 54, Tyumen, 625023


L. V. Kremneva
Tyumen Department of South Ural Research Center
Russian Federation
4th km Chervishevskogo tracta 7, Tyumen, 625000


O. V. Abaturova
Tyumen Medical Academy
Russian Federation
ul. Odesskaya 54, Tyumen, 625023


References

1. Baigent C., Keech A., Kearney P.M. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-78.

2. National guidelines for diagnosis and correction of disorders of lipid metabolism in order to prevent and treat atherosclerosis. Kardiovaskulyarnaya terapiya i profilaktika 2007; 6(6) prilozhenie 3:1—32. (Национальные рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Кардиоваскулярная терапия и профилактика 2007; 6(6) приложение 3:1-32).

3. Nicholls S.J., Tuzcu E.M., Sipahi I. et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol 2006;97(11):1553-7.

4. Scheen A.J. Clinical study of the month: ASTEROID: regression of coronary atherosclerosis with rosuvastatin at a maximal daily dose of 40 mg. Rev Med Liege 2006;61(4):267-72.

5. Dohi T., Miyauchi K., Okazaki S. et al. Early intensive statin treatment for six months improves longterm clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a followup study. Atherosclerosis 2010;210(2):497-502.

6. Extended ASCOT - lipid lowering (ASCOT-LLA) study shows positive results of atorvastatin. Cardiovasc J Afr 2008;19(1):49-51.

7. Charlton-Menys V., Betteridge D.J., Colhoun H. et al. Targets of statin therapy: LDL cholesterol, nonHDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative AtorvastatinDiabetes Study (CARDS). Clin Chem 2009;55(3):473-80.

8. Olsson A.G., Schwartz G.G., Szarek M. et al. Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am J Cardiol 2007;99(5):632-5.

9. Bangalore S., Qin J., Sloan S. et al. What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?: Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial. Circulation 2010;122(21):2142-2151.

10. Panchenko E.P. Mekhanizmy razvitiya ostrogo koronarnogo sindroma. Russkiy meditsinskiy zhurnal 2000;8 (109): 359-64. Russian (Панченко Е.П. Механизмы развития острого коронарного синдрома. РМЖ 2000;8 (109): 359-64).

11. Johnson C., Waters D.D., DeMicco D.A. et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis ofthe Treating to New Targets [TNT] Study). Am J Cardiol 2008;102(10):1312-7.

12. Pedersen T.R., Faergeman O., Kastelein J.J. et al. IncrementalDecrease in End Points ThroughAggressive Lipid Lowering (IDEAL) Study Group.High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. JAMA 2005;294(19):2437–2445.

13. Cannon C.P. , Braunwald E., McCabe C. et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New Engl J Med 2004;350(15):1495–1504.

14. Pasceri V., Cheng J.S., Willerson J.T., Yeh E.T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by antiatherosclerotic drugs. Circulation 2001; 103(21): 2531-4.

15. Yalymov A.A., Shekhyan G.G., Bylyeva A.A., Zadionchenko V.S. Lipid and pleiotropic effects of atorvastatin in patients with acute coronary syndrome. Kardiovaskulyarnaya terapiya i profilaktika 2009;8(7):64-72. Russian (Ялымов А.А., Шехин Г. Г., Быльева А.А., Задионченко В.С. Липидные и нелипидные эффекты аторвастатина у больных с острым коронарным синдромом. Кардиоваскулярная терапия и профилактика 2009;8(7):64-72).

16. Ridker P.M.,Danielson E., Fonseca F.A.H. et al. Rosuvastatin to prevent vascular events in men andwomen with elevated C-reactive protein. New Engl J Med 2008;359(21):2195-2207.

17. Nicholls S.J., Tuzcu E.M., Sipahi I. et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol 2006;97(11):1553-7.

18. Ridker P.M., Morrow D.A., Rose L.M. et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005;45(10):1644-8.

19. Mareev V.Yu. Atorvastatin in the Treatment ofHigh Risk Patients With IschemicHeart Disease and Dyslipidemia. Safety Assessment in the Russian Multicenter Study ATLANTIKA. Kardiologiia 2010;9:4-14. Russian (Мареев В.Ю. Аторвастатин в лечении больных ишемической болезнью сердца и дислипидемий и высоким общим риском (по результатам российского многоцентрового исследования АТЛАНТИКА): оценка безопасности. Кардиология 2010;9:4-14).

20. Susekov A.V., Rozhkova T.A., Tripoten" M.I. et al. Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness. Kardiovaskulyarnaya terapiya

21. i profilaktika 2007;6(3):68-75. Russian (Сусеков А.В., Рожкова Т.А., Трипотень М.И. и др. Рандомизированное исследование ФАРВАТЕР: Эффект аторвастатина на функцию эндотелия, растяжимость и жесткость сосудистой стенки. Кардиоваскулярная терапия и профилактика 2007;6(3):68-75).

22. Shalnova S.A., Deev A.D., Kiseleva N.V. Atorvastatin effectiveness and safety in patients with high cardiovascular risk. Revising the results of the OSCAR Study (2006). Kardiovaskulyarnaya terapiya i profilaktika 2010; 9(6): 57-62. Russian (Шальнова С.А., Деев А.Д., Киселева Н.В. Эффективность и безопасность аторвастатина у пациентов высокого сердечно-сосудистого риска. вновь вернемся к результатам российского исследования ОСКАР 2006. Кардиоваскулярная терапия и профилактика 2010; 9(6): 57-62).

23. Velavan P., Loh P.H., Clark A., Cleland J.G. Is the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) the answer to the cholesterol paradox in heart failure? Congest Heart Fail 2008;14(1):55.

24. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9645):1231-9.

25. Law M., Rudnicka A.R. Statin safety: a systemic review. Am J Cardiol 2006;97(8A):52C-60C.

26. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression ofrenal disease: a metaanalysis. Kidney Int 2001; 59(1): 260-9.

27. Wanner C., Krane V., Marz W. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353(3): 238-48.


For citation:


Shalaev S.V., Safiullina Z.M., Kremneva L.V., Abaturova O.V. COMPARATIVE EFFICACY OF THE STATINS IN PREVENTING AND TREATING OF THE CORONARY HEART DISEASE. Rational Pharmacotherapy in Cardiology. 2010;6(6):865-869. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-6-865-869

Views: 315


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)